Literature DB >> 8548545

Adenosine deaminase isoenzyme levels in patients with human T-cell lymphotropic virus type 1 and human immunodeficiency virus type 1 infections.

I Tsuboi1, K Sagawa, S Shichijo, M M Yokoyama, D W Ou, M D Wiederhold.   

Abstract

In serum, the enzyme adenosine deaminase (ADA) is known to be divided into two isoenzymes, ADA1 and ADA2, which have different molecular weights and kinetic properties. The present study investigated ADA isoenzyme levels in the sera of patients infected with retroviruses associated with adult T-cell leukemia (ATL), human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy (HAM), and AIDS, ADA isoenzyme activities were found to be significantly (P < 0.001) higher in the sera of patients with ATL, HAM, and AIDS than in the sera of healthy controls. In the case of the ADA subtypes in the sera of patients with ATL, ADA1 activity was significantly (P < 0.001) elevated in patients with the acute and lymphoma types of ATL compared with that in patients with the chronic and smoldering types of ATL. ADA2 activity was significantly elevated in the sera of patients with the acute, lymphoma, and chronic types of ATL (P < 0.001) compared with that in patients with smoldering ATL and HTLV-1 carriers. In the case of patients with human immunodeficiency virus type 1 (HIV-1) infection, ADA1 and ADA2 activities in the sera of patients with AIDS and HIV-1 antibody-positive individuals were significantly (P < 0.001) higher than those in the sera of HIV-1 antibody-negative individuals. A significant elevation in ADA2 activity was also seen in the sera of AIDS patients (P < 0.01) compared with that in the sera of HIV-1 antibody-positive individuals. These results suggest that the magnitude of elevation of ADA isoenzyme levels in serum correlates well with the clinical conditions of the patients with these diseases. Measurement of the activities of ADA isoenzymes may therefore provide an additional parameter for distinguishing the subtypes of ATL and may prove to be useful as prognostic and therapeutic monitors in diseases associated with HTLV-1 and HIV-1 infections.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8548545      PMCID: PMC170210          DOI: 10.1128/cdli.2.5.626-630.1995

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  25 in total

1.  Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition.

Authors:  H C Lane; J M Depper; W C Greene; G Whalen; T A Waldmann; A S Fauci
Journal:  N Engl J Med       Date:  1985-07-11       Impact factor: 91.245

2.  HTLV-I associated myelopathy, a new clinical entity.

Authors:  M Osame; K Usuku; S Izumo; N Ijichi; H Amitani; A Igata; M Matsumoto; M Tara
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

3.  Purine interconversion pathways in T, B, T gamma and T-T gamma cells from human peripheral blood.

Authors:  J P van Laarhoven; G T Spierenburg; H Collet; G Delespesse; C H De Bruyn
Journal:  Adv Exp Med Biol       Date:  1984       Impact factor: 2.622

4.  Serum adenosine deaminase in normals and in a patient with adenosine deaminase deficient-severe combined immunodeficiency.

Authors:  H Ratech; R Hirschhorn
Journal:  Clin Chim Acta       Date:  1981-09       Impact factor: 3.786

5.  Adenosine deaminase inhibitors. Conversion of a single chiral synthon into erythro- and threo-9-(2-hydroxy-3-nonyl)adenines.

Authors:  G Bastian; M Bessodes; R P Panzica; E Abushanab; S F Chen; J D Stoeckler; R E Parks
Journal:  J Med Chem       Date:  1981-12       Impact factor: 7.446

6.  The potential importance of soluble deoxynucleotidase activity in mediating deoxyadenosine toxicity in human lymphoblasts.

Authors:  D A Carson; J Kaye; D B Wasson
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

7.  Distribution of terminal deoxynucleotidyl transferase and purine degradative and synthetic enzymes in subpopulations of human thymocytes.

Authors:  D D Ma; T A Sylwestrowicz; S Granger; M Massaia; R Franks; G Janossy; A V Hoffbrand
Journal:  J Immunol       Date:  1982-10       Impact factor: 5.422

Review 8.  Purine metabolism in relation to leukemia and lymphoid cell differentiation.

Authors:  J P van Laarhoven; C H de Bruyn
Journal:  Leuk Res       Date:  1983       Impact factor: 3.156

9.  Adenosine deaminase in plasma of patients with adult T-cell leukemia (ATL): correlation between enzyme activity and the ATL subtypes.

Authors:  T Oda; T Kagimoto; N Aso; K Yamaguchi; S Tomino; K Takatsuki
Journal:  Hematol Oncol       Date:  1985 Jul-Sep       Impact factor: 5.271

10.  Comparison and possible homology of isozymes of adenosine deaminase in Aves and humans.

Authors:  H Ratech; G J Thorbecke; G Meredith; R Hirschhorn
Journal:  Enzyme       Date:  1981
View more
  14 in total

1.  Adenosine deaminase activity in serum and lymphocytes of rats infected with Sporothrix schenckii.

Authors:  Verônica S P Castro; Victor C Pimentel; Aleksandro S Da Silva; Gustavo R Thomé; Patrícia Wolkmer; Jorge L C Castro; Márcio M Costa; Cássia B da Silva; Daniele C Oliveira; Sydney H Alves; Maria R C Schetinger; Sonia T A Lopes; Cinthia M Mazzanti
Journal:  Mycopathologia       Date:  2011-12-15       Impact factor: 2.574

Review 2.  Adenosine signaling and adenosine deaminase regulation of immune responses: impact on the immunopathogenesis of HIV infection.

Authors:  Daniela F Passos; Viviane M Bernardes; Jean L G da Silva; Maria R C Schetinger; Daniela Bitencourt Rosa Leal
Journal:  Purinergic Signal       Date:  2018-08-10       Impact factor: 3.765

3.  Serum Adenosine Deaminase (ADA) Activity: A Novel Screening Test to Differentiate HIV Monoinfection From HIV-HBV and HIV-HCV Coinfections.

Authors:  Mohammad Abdi; Rizgar Rahbari; Zahed Khatooni; Nima Naseri; Adel Najafi; Iraj Khodadadi
Journal:  J Clin Lab Anal       Date:  2015-02-16       Impact factor: 2.352

4.  Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity.

Authors:  Andrey V Zavialov; Ake Engström
Journal:  Biochem J       Date:  2005-10-01       Impact factor: 3.857

5.  Serum adenosine deaminase activity in patients with systemic lupus erythematosus: a study based on ADA1 and ADA2 isoenzymes pattern.

Authors:  Reza Saghiri; Niloufar Ghashghai; Shafieh Movaseghi; Pegah Poursharifi; Shohreh Jalilfar; Manijeh Ahmadi Bidhendi; Leila Ghazizadeh; Mina Ebrahimi-Rad
Journal:  Rheumatol Int       Date:  2011-02-25       Impact factor: 2.631

6.  Immunological dysfunction in HIV-1-infected individuals caused by impairment of adenosine deaminase-induced costimulation of T-cell activation.

Authors:  José M Martinez-Navio; Núria Climent; Rodrigo Pacheco; Felipe Garcia; Montserrat Plana; Meritxell Nomdedeu; Harold Oliva; Cristina Rovira; Laia Miralles; José M Gatell; Teresa Gallart; Josefa Mallol; Carme Lluis; Rafael Franco
Journal:  Immunology       Date:  2009-11       Impact factor: 7.397

7.  Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2.

Authors:  Carmelo Carmona-Rivera; Sami S Khaznadar; Kyawt W Shwin; Jorge A Irizarry-Caro; Liam J O'Neil; Yudong Liu; Kenneth A Jacobson; Amanda K Ombrello; Deborah L Stone; Wanxia L Tsai; Daniel L Kastner; Ivona Aksentijevich; Mariana J Kaplan; Peter C Grayson
Journal:  Blood       Date:  2019-04-23       Impact factor: 25.476

8.  Warts and DADA2: a Mere Coincidence?

Authors:  Katrijn Arts; Jenna R E Bergerson; Amanda K Ombrello; Morgan Similuk; Andrew J Oler; Anahita Agharahimi; Emily M Mace; Mike Hershfield; Carine Wouters; Lien De Somer; Marie-Anne Morren; Rebeca Perez-de Diego; Leen Moens; Alexandra F Freeman; Isabelle Meyts
Journal:  J Clin Immunol       Date:  2018-11-01       Impact factor: 8.542

9.  Adenosine Deaminase-2-Induced Hyperpermeability in Human Retinal Vascular Endothelial Cells Is Suppressed by MicroRNA-146b-3p.

Authors:  Yara A Samra; Heba M Saleh; Khaled A Hussein; Nehal M Elsherbiny; Ahmed S Ibrahim; Khaled Elmasry; Sadanand Fulzele; Mamdouh M El-Shishtawy; Laila A Eissa; Mohamed Al-Shabrawey; Gregory I Liou
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-02-01       Impact factor: 4.799

10.  Elevated Serum ADA Activity as a Marker for Diagnosis and Prognosis of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis in Indian Patients.

Authors:  Ajay Amit; Manas R Dikhit; Raj K Pandey; Kuljit Singh; Ritesh Mishra; V N R Das; Pradeep Das; Sanjiva Bimal
Journal:  PLoS One       Date:  2016-05-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.